Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell presented an overview of the company at the Proactive One2One Investor Forum. Arecor, listed on AIM since 2021, focuses on enhancing existing therapeutic medicines to improve patient care. Howell's background includes product development at GSK and UCB, and she previously led M&A at BTG (LSE:BTG) before its acquisition by Boston Scientific.
Arecor leverages a proprietary technology platform to improve the safety, efficacy, and usability of existing medicines. The company partners with major pharma and biotech firms under a milestone and royalty-bearing licensing model. One of their partner products has already been launched, generating recurring royalties. They also have products licensed with companies like Sanofi and Hikma.
Arecor's in-house proprietary products target high unmet needs in large markets, focusing on diabetes and obesity. They aim to use their technology to create ready-to-use versions of hospital medications, reducing errors and improving workflow efficiency. Howell highlighted the diabetes product AT278, a highly concentrated rapid-acting insulin, which targets a $6.4 billion market.
Arecor's financials show growing revenue streams, with a 9% increase from FY22 to FY23, and a cash position of £6.8 million at the end of FY23. The company anticipates continued growth through existing partnerships and potential new licensing deals, with significant upside from their proprietary insulin products.
